Results 31 to 40 of about 2,693 (166)

Y-site Administration of Imipenem/Cilastatin/Relebactam With Common Intravenous Medications [PDF]

Clinical Therapeutics, 2020
Imipenem/cilastatin/relebactam has shown efficacy in complicated intra-abdominal and urinary tract infections in the RESTORE IMI-1 study, and it was recently approved by the US Food and Drug Administration. A press release announced that another Phase III study (RESTORE IMI-2) in patients with hospital-acquired and ventilator-associated pneumonia has ...
Islam M, Ghazi, Wasim S, El Nekidy, Ayush, Sood, Amanpreet, Dulku, Radha, Patel, Krishna, Patel, Pengfei, Li   +6 more
openaire   +2 more sources

Infections Caused by Carbapenem-Resistant Enterobacteriaceae: An Update on Therapeutic Options

Frontiers in Microbiology, 2019
Carbapenems are considered as last-resort antibiotics for the treatment of infections caused by multidrug-resistant Gram-negative bacteria. With the increasing use of carbapenems in clinical practice, the emergence of carbapenem-resistant pathogens now ...
Chau-Chyun Sheu, Chau-Chyun Sheu, Ya-Ting Chang, Ya-Ting Chang, Shang-Yi Lin, Shang-Yi Lin, Yen-Hsu Chen, Yen-Hsu Chen, Yen-Hsu Chen, Po-Ren Hsueh, Po-Ren Hsueh   +10 more
doaj   +1 more source

Allergic Reactions and Cross-Reactivity Potential with Beta-Lactamase Inhibitors

Pharmacy, 2019
Although beta-lactam allergies are an emerging focus of stewardship programs and interventions, less is publicly released regarding allergies to beta-lactamase inhibitors. This review presents and evaluates the data regarding allergic reactions with beta-
Kayla R. Stover, Katie E. Barber, Jamie L. Wagner   +2 more
doaj   +1 more source

Rapid Detection of KPC-Producing Enterobacterales Susceptible to Imipenem/Relebactam by Using the MALDI-TOF MS MBT STAR-Carba IVD Assay

Frontiers in Microbiology, 2020
KPC-producing Enterobacterales represent a serious public health concern. Limited therapeutic options are available for treatment, however, the novel combination of imipenem/relebactam represents a promising alternative.
Marina Oviaño, Eva Gato, Germán Bou
doaj   +1 more source

Recent Developments to Cope the Antibacterial Resistance via β-Lactamase Inhibition

Molecules, 2022
Antibacterial resistance towards the β-lactam (BL) drugs is now ubiquitous, and there is a major global health concern associated with the emergence of new β-lactamases (BLAs) as the primary cause of resistance.
Zafar Iqbal, Jian Sun, Haikang Yang, Jingwen Ji, Lili He, Lijuan Zhai, Jinbo Ji, Pengjuan Zhou, Dong Tang, Yangxiu Mu, Lin Wang, Zhixiang Yang   +11 more
doaj   +1 more source

A Clinical Review and Critical Evaluation of Imipenem-Relebactam: Evidence to Date.

Infection and drug resistance, 2020
Imipenem-relebactam (I-R) is a novel beta-lactam/beta-lactamase inhibitor combination given with cilastatin. It is indicated for the treatment of complicated urinary tract infections, complicated intra-abdominal infections, and hospital-acquired or ventilator-associated bacterial pneumonia.
Campanella,Toni A, Gallagher,Jason C
openaire   +5 more sources

In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales

Antibiotics, 2023
Background: Avibactam, relebactam and vaborbactam are β-lactamase inhibitors that proved their efficiency against KPC-producing Enterobacterales. Regarding their inhibitor activity towards Ambler’s class A extended spectrum β-lactamases (ESBL) and Ambler’
Rémy A. Bonnin, Sandrine Bernabeu, Cécile Emeraud, Thierry Naas, Delphine Girlich, Agnès B. Jousset, Laurent Dortet   +6 more
doaj   +1 more source

The Effectiveness of Imipenem–Relebactam against Ceftazidime-Avibactam Resistant Variants of the KPC-2 β-Lactamase

Antibiotics, 2023
Background: Ceftazidime-avibactam was approved by the FDA to treat infections caused by Enterobacterales carrying blaKPC-2. However, variants of KPC-2 with amino acid substitutions at position 179 have emerged and confer resistance to ceftazidime ...
Krisztina M. Papp-Wallace, Melissa D. Barnes, Magdalena A. Taracila, Christopher R. Bethel, Joseph D. Rutter, Elise T. Zeiser, Katherine Young, Robert A. Bonomo   +7 more
doaj   +1 more source

Synergistic Effect of Clinically Available Beta-Lactamase Inhibitors Combined with Cefiderocol against Carbapenemase-Producing Gram-Negative Organisms

Antibiotics, 2022
The role of β-lactamases in reduced susceptibility or resistance to cefiderocol has been supported by recent reports. The purpose of this study was to investigate the in vitro impact of clinically available β-lactamase inhibitors on cefiderocol activity ...
Gabriele Bianco, Paolo Gaibani, Sara Comini, Matteo Boattini, Giuliana Banche, Cristina Costa, Rossana Cavallo, Patrice Nordmann   +7 more
doaj   +1 more source

In Vitro Activity of Imipenem/Relebactam Alone and in Combination Against Cystic Fibrosis Isolates of Mycobacterium abscessus

Antibiotics
Background: Mycobacterium abscessus (MABS) is an opportunistic pathogen that causes chronic, difficult-to-treat pulmonary infections, particularly in people with cystic fibrosis (PwCF), leading to rapid lung function decline and increased morbidity and ...
Madeline Sanders, Sun Woo Kim, Aditi Shinde, Danielle Fletcher-Williams, Eric Quach, Paul Beringer   +5 more
doaj   +1 more source